U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C20H15Cl3N2OS
Molecular Weight 437.77
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ARASERTACONAZOLE

SMILES

ClC1=CC(Cl)=C(C=C1)[C@H](CN2C=CN=C2)OCC3=CSC4=C(Cl)C=CC=C34

InChI

InChIKey=JLGKQTAYUIMGRK-IBGZPJMESA-N
InChI=1S/C20H15Cl3N2OS/c21-14-4-5-16(18(23)8-14)19(9-25-7-6-24-12-25)26-10-13-11-27-20-15(13)2-1-3-17(20)22/h1-8,11-12,19H,9-10H2/t19-/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: http://www.rxlist.com/ertaczo-drug.htm https://www.drugs.com/mtm/sertaconazole-topical.html http://www.wikidoc.org/index.php/Sertaconazole

Sertaconazole is a azole antifungal that is FDA approved for the treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older, caused by: Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum. Sertaconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Common adverse reactions include contact dermatitis, dry skin, burning skin and application site skin tenderness.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
ERTACZO

Approved Use

ERTACZO® (sertaconazole nitrate) Cream, 2%, is indicated for the topical treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older, caused by: Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum (see CLINICAL STUDIES Section).

Launch Date

2003
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.79 ng/mL
300 mg single, vaginal
dose: 300 mg
route of administration: Vaginal
experiment type: SINGLE
co-administered:
SERTACONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
43.31 ng × h/mL
300 mg single, vaginal
dose: 300 mg
route of administration: Vaginal
experiment type: SINGLE
co-administered:
SERTACONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
20.25 h
300 mg single, vaginal
dose: 300 mg
route of administration: Vaginal
experiment type: SINGLE
co-administered:
SERTACONAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
SERTACONAZOLE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 % 2 times / day steady, topical
Highest studied dose
Dose: 2 %, 2 times / day
Route: topical
Route: steady
Dose: 2 %, 2 times / day
Sources: Page: 6.1
healthy, adult
n = 202
Health Status: healthy
Age Group: adult
Sex: unknown
Population Size: 202
Sources: Page: 6.1
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
In vitro comparative study of the fungistatic and fungicidal activity of sertaconazole and other antifungals against Candida albicans.
1992 May
In vitro antifungal activity of sertaconazole.
1992 May
In vitro activity of sertaconazole.
1992 May
In-vitro antifungal activity of sertaconazole, econazole, and bifonazole against Candida spp.
1995 Oct
Antifungal activity of sertaconazole in vitro against clinical isolates of Candida spp.
1996 Mar-Apr
Comparative study of antifungal activity of sertaconazole, terbinafine, and bifonazole against clinical isolates of Candida spp., Cryptococcus neoformans and dermatophytes.
1997 Nov-Dec
Patents

Sample Use Guides

Cream should be applied to the affected and immediate surrounding area(s) twice daily for 4 weeks.
Route of Administration: Topical
In Vitro Use Guide
MIC for Candida parapsilosis (0.26 mg/l) demonstrated a higher activity of sertaconazole against this species, in contrast to Candida tropicalis (MIC 1.49 mg/l). Against dermatophytes, MIC for sertaconazole was MIC 0.41 mg/l and against Cryptococcus neoformans yeasts - arithmetic mean MIC 1.24 mg/l.
Name Type Language
ARASERTACONAZOLE
INN  
INN  
Official Name English
1H-IMIDAZOLE, 1-((2R)-2-((7-CHLOROBENZO(B)THIEN-3-YL)METHOXY)-2-(2,4-DICHLOROPHENYL)ETHYL)-
Systematic Name English
SERTACONAZOLE, (R)-
Common Name English
arasertaconazole [INN]
Common Name English
1-((2R)-2-((7-CHLORO-1-BENZOTHIOPHEN-3-YL)METHOXY)-2-(2,4-DICHLOROPHENYL)ETHYL)-1H-IMIDAZOLE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C514
Created by admin on Fri Dec 15 17:19:53 GMT 2023 , Edited by admin on Fri Dec 15 17:19:53 GMT 2023
Code System Code Type Description
FDA UNII
PR82C5R514
Created by admin on Fri Dec 15 17:19:53 GMT 2023 , Edited by admin on Fri Dec 15 17:19:53 GMT 2023
PRIMARY
CHEBI
83685
Created by admin on Fri Dec 15 17:19:53 GMT 2023 , Edited by admin on Fri Dec 15 17:19:53 GMT 2023
PRIMARY
EPA CompTox
DTXSID00207032
Created by admin on Fri Dec 15 17:19:53 GMT 2023 , Edited by admin on Fri Dec 15 17:19:53 GMT 2023
PRIMARY
ChEMBL
CHEMBL1410877
Created by admin on Fri Dec 15 17:19:53 GMT 2023 , Edited by admin on Fri Dec 15 17:19:53 GMT 2023
PRIMARY
INN
8554
Created by admin on Fri Dec 15 17:19:53 GMT 2023 , Edited by admin on Fri Dec 15 17:19:53 GMT 2023
PRIMARY
SMS_ID
300000036865
Created by admin on Fri Dec 15 17:19:53 GMT 2023 , Edited by admin on Fri Dec 15 17:19:53 GMT 2023
PRIMARY
PUBCHEM
6604451
Created by admin on Fri Dec 15 17:19:53 GMT 2023 , Edited by admin on Fri Dec 15 17:19:53 GMT 2023
PRIMARY
CAS
583057-48-1
Created by admin on Fri Dec 15 17:19:53 GMT 2023 , Edited by admin on Fri Dec 15 17:19:53 GMT 2023
PRIMARY
NCI_THESAURUS
C79926
Created by admin on Fri Dec 15 17:19:53 GMT 2023 , Edited by admin on Fri Dec 15 17:19:53 GMT 2023
PRIMARY